Novartis and Quark to co-develop new RNAi-based drug

Novartis is to partner with RNAi-based therapeutics specialist Quark Pharmaceuticals on the development of a new p53 temporary inhibitor siRNA drug.

The company has secured an exclusive global licence to develop and commercialise QPI-1002, a treatment which is currently undergoing phase II clinical testing.

It is designed to help prevent acute kidney injury in cardiac surgery patients and delayed graft function for kidney transplant patients, functioning by targeting p53, a key agent in apoptotic cell death.

The deal will see Quark receive up to $670 million (431 million pounds) in milestone payments and option exercise fees from Novartis, as well as being entitled to a share of any royalties.

Dr Daniel Zurr, Quark's chief executive officer, said: "We believe that Novartis represents an outstanding partner for Quark. With its world-leading expertise in transplantation and acute care, Novartis will provide invaluable support to the global development of QPI-1002."

Earlier this month, Novartis launched Onbrez Breezhaler in the UK, a new drug specified for the treatment of chronic obstructive pulmonary disease among adult patients.